The clinical information you need, at your fingertips.

New indication allows clinicians to use the once-weekly dual GIP/GLP-1 receptor agonist to address cardiovascular risk in addition to glycemic control. . .

A model built from routine records identified people at high risk of hip fracture years in advance with no in-person assessment. . .

Frequent use of short-acting bronchodilators, especially SAMA-containing inhalers, was associated with higher cardiovascular event rates and mortality in a large real-world study. . .

Scientific statement highlights red flags for secondary Raynaud phenomenon, emerging diagnostic tools, and evidence-based treatment options. . .

Men taking 5-alpha reductase inhibitors had fewer serious complications after PCI-treated STEMI in a large Swedish registry study. . .